36.73

2.44% -0.92

Pre-market: 37.34 0.61 +1.66%

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $36.73, with a volume of 2.30M. It is down -2.44% in the last 24 hours and down -15.11% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$37.65

Open:

$37.49

24h Volume:

2.30M

Relative Volume:

0.86

Market Cap:

$4.94B

Revenue:

Net Income/Loss:

$-237.54M

P/E Ratio:

-14.67

EPS:

-2.5033

Net Cash Flow:

$-145.05M

1W Performance:

-5.04%

1M Performance:

-15.11%

6M Performance:

+106.46%

1Y Performance:

+0.00%

1-Day Range:

$35.89

$37.60

1-Week Range:

$35.89

$40.39

52-Week Range:

$14.62

$49.70

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	36.73	4.94B	0	-237.54M	-145.05M	-2.5033
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Stifel	Buy
Apr-10-26	Initiated	Piper Sandler	Overweight
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

Sep 24, 2026

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression - Yahoo Finance

Sep 24, 2026

Sep 23, 2026